Eine Phase -3 (EMBRACE)
Eine Wirksamkeit und Sicherheit, Phase-III, multizentrische, doppelblinde, randomisierte kontrollierte Studie zum Vergleich von 2 aktiven Dosen von CyB003 und Placebo bei berechtigten Teilnehmern mit einer schweren depressiven Störung
The purpose of this study is to determine the efficacy, safety and tolerability of CYB003 compared to matching placebo as adjunctive treatment in patients with MDD.
For more information about the EMBRACE study, including participating study locations, and to register your interest in learning more about participation, please visit the study website: https://embrace-mdd-trial.com/
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Phase 3
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Clinical Development
- Telefonnummer: 877-361-4003
- E-Mail: clinicaltrialsinfo@cybin.com
Studienorte
-
-
New South Wales
-
Camperdown, New South Wales, Australien, 2050
- Rekrutierung
- Royal Prince Alfred Hospital
-
Hauptermittler:
- Nicholas Glozier
-
-
Queensland
-
Maroochydore, Queensland, Australien, 4558
- Rekrutierung
- Thompson Brain & Mind Healthcare (TBMH)
-
Hauptermittler:
- Adem Can
-
Kontakt:
- Megan Dutton
- Telefonnummer: +61 4160 40977
- E-Mail: mdutton@tbmh.org.au
-
Kontakt:
- Kristy Smyth
- Telefonnummer: +61 4324 41227
- E-Mail: ksmyth@tbmh.org.au
-
-
Victoria
-
Melbourne, Victoria, Australien, 3004
- Rekrutierung
- Ramsay Clinic
-
Hauptermittler:
- Malcolm Hopwood
-
Kontakt:
- Melanie Hurley
- Telefonnummer: 03 9279 3569
- E-Mail: research.arc@ramsayhealth.com.au
-
Kontakt:
- Grace Monigatti
- Telefonnummer: 03 9279 3569
- E-Mail: research.arc@ramsayhealth.com.au
-
Melbourne, Victoria, Australien, 3053
- Rekrutierung
- Neurocentrix Research
-
Hauptermittler:
- David Barton
-
Kontakt:
- Mai-Anh Bui
- Telefonnummer: +61 3 9546 0009
- E-Mail: mai@neurocentrix.com.au
-
Kontakt:
- Gabriela Gonzalez
- Telefonnummer: +61 3 9959 8375
- E-Mail: gabriela@neurocentrix.com.au
-
Notting Hill, Victoria, Australien, 3168
- Rekrutierung
- Monash University - Notting Hill
-
Kontakt:
- Olivia Lavalette
- Telefonnummer: 0426359494
- E-Mail: olivia.lavalette@monash.edu
-
Hauptermittler:
- Paul Liknaitzky
-
-
-
-
-
Berlin, Deutschland, 10117
- Noch keine Rekrutierung
- Charité Universitaetsmedizin Berlin
-
Hauptermittler:
- Michael Koslowski
-
Kontakt:
- Telefonnummer: +49 30 450 617734
- E-Mail: psychedelika-studien@charite.de
-
Frankfurt am Main, Deutschland, 60528
- Noch keine Rekrutierung
- University Hospital Frankfurt
-
Hauptermittler:
- Andreas Reif
-
Kontakt:
- Tanja Scharf
- Telefonnummer: +49 69 6301 86078
- E-Mail: tanja.scharf@unimedizin-ffm.de
-
Mannheim, Deutschland, 68159
- Noch keine Rekrutierung
- Central Institute of Mental Health
-
Kontakt:
- Karin Bopp
- Telefonnummer: 3016 +49 621 1703 3163
- E-Mail: Karin.bopp@zi-mannheim.de
-
Hauptermittler:
- Gerhard Grüender
-
-
Saarland
-
Homburg, Saarland, Deutschland, 66421
- Noch keine Rekrutierung
- Universitätsklinikum des Saarlandes und Medizinische Fakultät der Universität des Saarlandes
-
Hauptermittler:
- Matthias Riemenschneider
-
Kontakt:
- Christine Geiger
- Telefonnummer: +49 6841 1624227
- E-Mail: christine.geiger@uks.eu
-
Kontakt:
- Aline Freer
- Telefonnummer: +49 6841 1614219
- E-Mail: aline.freer@uks.eu
-
-
-
-
-
Athens, Griechenland, 12462
- Rekrutierung
- Attikon University Hospital
-
Hauptermittler:
- Nikolaos Smyrnis
-
Kontakt:
- Thomas Karantinos
- Telefonnummer: +30697466610
- E-Mail: tkarantinos@gmail.com
-
Athens, Griechenland, 11528
- Rekrutierung
- Eginitio Hospital
-
Hauptermittler:
- Nikos Stefanis
-
Kontakt:
- Adam Adamopoulos
- Telefonnummer: +30 6976032181
- E-Mail: adam_adamopoulos@yahoo.com
-
Thessaloniki, Griechenland, 56404
- Rekrutierung
- Papageorgiou General Hospital
-
Hauptermittler:
- Georgios Papazisis
-
Kontakt:
- Ogla Vampertzi
- Telefonnummer: +306973852659
- E-Mail: olgatrieste@hotmail.com
-
-
-
-
-
Dublin, Irland, D24 WK80
- Rekrutierung
- Sheaf House - Tallaght Adult Mental Health Service
-
Hauptermittler:
- John Kelly
-
Kontakt:
- Ann Connolly
- Telefonnummer: +353 8616 79619
- E-Mail: aconnolly@crp.healthcare
-
Galway, Irland, H91 VE03
- Rekrutierung
- La Nua Day Hospital Mental Health Centre
-
Kontakt:
- Prathyusha Nedunuru
- Telefonnummer: +353 874283750
- E-Mail: pnedunuru@crp.healthcare
-
Hauptermittler:
- Shane McInerney
-
-
-
-
-
Bialystok, Polen, 15-272
- Zurückgezogen
- Uniwersytecki Szpital Kliniczny W Białymstoku
-
Bydgoszcz, Polen, 85-133
- Rekrutierung
- Promente - Centrum Neurologii i Psychogeriatrii w Bydgoszczy
-
Kontakt:
- Franciszek Lauchut
- Telefonnummer: +48 790 219 501
- E-Mail: f.lachut@pro-mente.pl
-
Hauptermittler:
- Katarzyna Lachut
-
Gdansk, Polen, 80-546
- Rekrutierung
- Centrum Badan Klinicznych PI-House Sp. z o.o
-
Kontakt:
- Monika Drzewiecka
- Telefonnummer: +48 508-348-938
- E-Mail: m.drzewiecka@pihouse.pl
-
Hauptermittler:
- Hanna Badzio-Jagiello
-
Gdansk, Polen, 80-214
- Noch keine Rekrutierung
- UCK
-
Hauptermittler:
- Wieslaw Jerzy Cubala
-
Kontakt:
- Natalia Sudol
- Telefonnummer: +48 669 439 740
- E-Mail: nat.sudol13@gmail.com
-
Warsaw, Polen, 02-957
- Noch keine Rekrutierung
- Department of Pharmacology and Physiology of CNS
-
Hauptermittler:
- Justyna Holka-Pokorska
-
Warsaw, Polen, 02-172
- Rekrutierung
- MTZ Clinical Research Powered by Pratia
-
Hauptermittler:
- Monika Gawlowicz
-
-
-
-
-
Prague, Tschechien
- Noch keine Rekrutierung
- Institute of neuropsychiatric Care (INEP)
-
Hauptermittler:
- Alexander Nawka
-
Kontakt:
- Telefonnummer: +420 222 201 020
- E-Mail: info@inep.cz
-
Prague, Tschechien
- Noch keine Rekrutierung
- Psyon s.r.o.
-
Hauptermittler:
- Tomas Palenicek
-
Kontakt:
- Telefonnummer: +420 774 401 161
- E-Mail: info@psyon.cz
-
Předměstí, Tschechien
- Noch keine Rekrutierung
- A-SHINE s.r.o.
-
Hauptermittler:
- Lubos Janu
-
Kontakt:
- Blanka Vopelková
- Telefonnummer: +490 777 732 244
- E-Mail: blanka.vopelkova@seznam.cz
-
-
-
-
Alabama
-
Birmingham, Alabama, Vereinigte Staaten, 35209
- Rekrutierung
- UAB Psychiatry and Behavioral Neurology
-
Kontakt:
- Seher Premani
- Telefonnummer: 205-996-1198
- E-Mail: spremani@uab.edu
-
Hauptermittler:
- Peter Hendricks
-
Kontakt:
- Maggie Gossage
- E-Mail: mgossage@uabmc.edu
-
-
Arizona
-
Gilbert, Arizona, Vereinigte Staaten, 85234
- Rekrutierung
- Lighthouse Psychiatry
-
Kontakt:
- Chung Trinh
- Telefonnummer: 435-268-5800
- E-Mail: ctrinh@neosciclinicalresearch.com
-
Hauptermittler:
- Frank Genova
-
-
Arkansas
-
Little Rock, Arkansas, Vereinigte Staaten, 72204
- Zurückgezogen
- Pillar Clinical Research - Little Rock
-
-
California
-
Glendale, California, Vereinigte Staaten, 91206
- Rekrutierung
- Behavioral Research Specialists, LLC
-
Hauptermittler:
- Jesse Carr
-
Kontakt:
- Laisha Uribe
- Telefonnummer: 888-255-5798
- E-Mail: laisha@brstrials.com
-
Imperial, California, Vereinigte Staaten, 92251
- Zurückgezogen
- Sun Valley Research Center
-
Los Angeles, California, Vereinigte Staaten, 90025
- Rekrutierung
- CalNeuro Research Group
-
Hauptermittler:
- Alexander Bystritsky
-
Kontakt:
- Telefonnummer: 310-208-7144
- E-Mail: info@calneuroresearch.com
-
Los Angeles, California, Vereinigte Staaten, 90025
- Rekrutierung
- Lipov Medical Group
-
Kontakt:
- Brittany Juhlmann
- Telefonnummer: 262-352-8835
- E-Mail: brittany.juhlmann@stellacenter.com
-
Hauptermittler:
- Jacob Moussai
-
Orange, California, Vereinigte Staaten, 92868
- Rekrutierung
- NRC Research Institute
-
Kontakt:
- Christian Ortiz
- Telefonnummer: 714-289-1100
- E-Mail: cortiz@nrcresearch.com
-
Hauptermittler:
- Daniel Chueh
-
Orange, California, Vereinigte Staaten, 92866
- Rekrutierung
- ATP Clinical Research
-
Hauptermittler:
- Gustavo Alva
-
Kontakt:
- Sarah Perkins
- Telefonnummer: 949-354-5353
- E-Mail: sarahp@pnsoc.com
-
San Juan Capistrano, California, Vereinigte Staaten, 92675
- Rekrutierung
- Inland Psychiatric Medical Group Inc (IPMG Research)
-
Hauptermittler:
- Neelima Kunam
-
Kontakt:
- Telefonnummer: 909-955-5865
- E-Mail: research@inlandpsych.com
-
Santa Monica, California, Vereinigte Staaten, 90404
- Rekrutierung
- Psychedelic Science Institute
-
Hauptermittler:
- Keith Heinzerling
-
Kontakt:
- Telefonnummer: 213-973-7512
- E-Mail: trialadmin@psychedelicsci.com
-
Stanford, California, Vereinigte Staaten, 94305
- Zurückgezogen
- Stanford University
-
-
Connecticut
-
New Haven, Connecticut, Vereinigte Staaten, 06511
- Rekrutierung
- Yale School of Medicine - Yale Program for Psychedelic Science
-
Hauptermittler:
- Ben Kelmendi
-
Kontakt:
- Daidre Chamberlain
- Telefonnummer: 203-693-1591
- E-Mail: enact@yale.edu
-
Kontakt:
- Terrence Ching
- Telefonnummer: 502-612-1127
- E-Mail: terence.ching@yale.edu
-
-
Florida
-
Jacksonville, Florida, Vereinigte Staaten, 32256
- Rekrutierung
- CNS Healthcare
-
Kontakt:
- Telefonnummer: 904-281-5757
-
Hauptermittler:
- John Mark Joyce
-
Maitland, Florida, Vereinigte Staaten, 32751
- Rekrutierung
- Accel Research Sites - Maitland
-
Kontakt:
- Telefonnummer: 407-644-1165
-
Hauptermittler:
- Andrea Marrafino
-
Naples, Florida, Vereinigte Staaten, 34105
- Rekrutierung
- Aqualane Clinical Research
-
Hauptermittler:
- Matthew Baker
-
Kontakt:
- Rachel Novella
- Telefonnummer: 239-529-6780
- E-Mail: Rachel@Aqualaneresearch.com
-
Tampa, Florida, Vereinigte Staaten, 33634
- Rekrutierung
- K2 Medical Research Tampa
-
Hauptermittler:
- Kelley Wilson
-
Kontakt:
- Jessica Myers
- Telefonnummer: 352-500-5252
- E-Mail: Jessica.Myers@k2med.com
-
-
Georgia
-
Atlanta, Georgia, Vereinigte Staaten, 30329
- Zurückgezogen
- Emory University Dept of Psychiatry and Behavioral Studies
-
Marietta, Georgia, Vereinigte Staaten, 30060
- Rekrutierung
- Psych Atlanta
-
Hauptermittler:
- Michael Banov
-
Kontakt:
- Telefonnummer: 770-422-2846
- E-Mail: research@hightophealth.com
-
-
Illinois
-
Chicago, Illinois, Vereinigte Staaten, 60612
- Rekrutierung
- Rush University
-
Hauptermittler:
- Joshua Eloge
-
Kontakt:
- Stephanie Gutierrez
- Telefonnummer: 312-942-8995
- E-Mail: stephanie_z_gutierrez@rush.edu
-
-
Louisiana
-
Marrero, Louisiana, Vereinigte Staaten, 70006
- Zurückgezogen
- Tandem Clinical Research
-
New Orleans, Louisiana, Vereinigte Staaten, 70115
- Rekrutierung
- Atlas Psychiatry
-
Kontakt:
- Milton Boresoff
- Telefonnummer: 504-899-1682
- E-Mail: m.boresoff@atlaspsychiatry.com
-
Hauptermittler:
- Nicholas Pejic
-
-
Maryland
-
Baltimore, Maryland, Vereinigte Staaten, 21224
- Zurückgezogen
- Johns Hopkins Medicine
-
Rockville, Maryland, Vereinigte Staaten, 20850
- Noch keine Rekrutierung
- Sunstone Medical, PC
-
Kontakt:
- Manish Agrawal, MD
- Telefonnummer: 301-750-3401
- E-Mail: Manish.agrawal@sunstonetherapies.com
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02116
- Rekrutierung
- Adams Clinical Boston
-
Hauptermittler:
- Darin Dougherty
-
Kontakt:
- Participant Navigators
- Telefonnummer: 617-404-4714
- E-Mail: info@adamsclinical.com
-
Watertown, Massachusetts, Vereinigte Staaten, 02472
- Rekrutierung
- Adams Clinical Watertown
-
Hauptermittler:
- Stephanie Ellickson
-
Kontakt:
- Participant Navigators
- Telefonnummer: 617-404-4714
- E-Mail: info@adamsclinical.com
-
-
Minnesota
-
Eden Prairie, Minnesota, Vereinigte Staaten, 55347
- Rekrutierung
- Institute for Integrative Therapies
-
Hauptermittler:
- Manoj Doss
-
Kontakt:
- Sena Ostwalt
- Telefonnummer: 6512808774
- E-Mail: sena.ostwalt@iit-mn.com
-
Golden Valley, Minnesota, Vereinigte Staaten, 55427
- Noch keine Rekrutierung
- The Remedy Mental Health
-
Kontakt:
- Emmanuel Arhin
- Telefonnummer: (651) 382-9518
- E-Mail: emmanuel.arhin@theremedymn.com
-
Hauptermittler:
- Wayne Bentham
-
-
Nevada
-
Las Vegas, Nevada, Vereinigte Staaten, 89119
- Rekrutierung
- Redbird Research, LLC
-
Hauptermittler:
- Jelena Kunovac
-
Kontakt:
- Telefonnummer: 702-577-2000
- E-Mail: info@redbird-research.com
-
-
New Jersey
-
Toms River, New Jersey, Vereinigte Staaten, 08755
- Rekrutierung
- Bio Behavioral Health
-
Kontakt:
- Jessica Sutton
- Telefonnummer: 732-244-2299
- E-Mail: jessica@bbhnj.com
-
Hauptermittler:
- Ashok Patel
-
-
New York
-
New York, New York, Vereinigte Staaten, 10032
- Noch keine Rekrutierung
- New York State Psychiatric Institute
-
Hauptermittler:
- Natalie Gukasyan
-
Kontakt:
- Alexandra Mackay
- Telefonnummer: 212-342-1424
- E-Mail: alexandra.mackay@nyspi.columbia.edu
-
New York, New York, Vereinigte Staaten, 10029
- Rekrutierung
- Adams Clinical Harlem
-
Kontakt:
- Participant Navigators
- Telefonnummer: 917-454-3746
- E-Mail: info@adamsclinical.com
-
Hauptermittler:
- Wesley Gregory
-
The Bronx, New York, Vereinigte Staaten, 10461
- Rekrutierung
- Adams Clinical Bronx
-
Hauptermittler:
- Shama Farooq
-
Kontakt:
- Participant Navigators
- Telefonnummer: 917-454-3746
- E-Mail: info@adamsclinical.com
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Vereinigte Staaten, 73112
- Zurückgezogen
- SP Research PLLC
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19104
- Rekrutierung
- Adams Clinical Philadelphia
-
Hauptermittler:
- Cassie Blanchard
-
Kontakt:
- Participant Navigators
- Telefonnummer: 267-376-0266
- E-Mail: info@adamsclinical.com
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19462
- Rekrutierung
- Flourish Research Philadelphia
-
Hauptermittler:
- Rachna Saralkar
-
Kontakt:
- Telefonnummer: 215-614-5606
-
-
Texas
-
Austin, Texas, Vereinigte Staaten, 78737
- Zurückgezogen
- Austin Clinical Trial Partners
-
DeSoto, Texas, Vereinigte Staaten, 75115
- Rekrutierung
- Adams Clinical Dallas
-
Hauptermittler:
- Rajinder Shiwach
-
Kontakt:
- Participant Navigators
- Telefonnummer: 469-379-2494
- E-Mail: info@adamsclinical.com
-
Fort Worth, Texas, Vereinigte Staaten, 76104
- Zurückgezogen
- North Texas Clinical Trials
-
Houston, Texas, Vereinigte Staaten, 77046
- Rekrutierung
- Brain Health Consultants and TMS Center
-
Hauptermittler:
- Lauren Marangell
-
Kontakt:
- Telefonnummer: 713-489-5000
- E-Mail: info@brainhealthconsultants.com
-
San Antonio, Texas, Vereinigte Staaten, 78229
- Rekrutierung
- Flourish Research San Antonio
-
Hauptermittler:
- Parke Hedges
-
Kontakt:
- Xavier Martinez
- Telefonnummer: 237 210-949-0122
- E-Mail: xmartinez@flourishresearch.com
-
Kontakt:
- Andrea Gomez
- Telefonnummer: 122 210-949-0122
- E-Mail: agomez@flourishresearch.com
-
-
Washington
-
Everett, Washington, Vereinigte Staaten, 98201
- Noch keine Rekrutierung
- Core Clinical Research
-
Kontakt:
- Maria Golescu
- Telefonnummer: 425-443-9551
- E-Mail: maria.golescu@ccrtrial.com
-
Hauptermittler:
- James Knutson
-
Seattle, Washington, Vereinigte Staaten, 98104
- Rekrutierung
- Seattle Neuropsychiatric Treatment Center
-
Hauptermittler:
- Rebecca Allen
-
Kontakt:
- Telefonnummer: 5 206-467-6300
- E-Mail: research@seattlentc.com
-
-
-
-
-
Cambridge, Vereinigtes Königreich, CB1 2EU
- Rekrutierung
- Cambridge University Hospital NHS
-
Hauptermittler:
- Liliana Galindo
-
Kontakt:
- Tracy Assari
- Telefonnummer: +44 1223 219751
- E-Mail: t.assari@nhs.net
-
Kontakt:
- Emma Tudor
- Telefonnummer: +44 1223 219751
- E-Mail: Emma.tudor@cpft.nhs
-
Doncaster, Vereinigtes Königreich, DN4 8QN
- Rekrutierung
- Clerkenwell Health - Doncaster
-
Hauptermittler:
- Paul Morrison
-
Kontakt:
- Celia Creaghan
- Telefonnummer: +44 7849 640886
- E-Mail: ccreaghan@clerkenwellhealth.com
-
Edinburgh, Vereinigtes Königreich, EH16 4TJ
- Noch keine Rekrutierung
- NHS Research Scotland
-
Hauptermittler:
- Donald MacIntyre
-
Kontakt:
- Carrie Wardhaugh
- Telefonnummer: +44 1315375867
- E-Mail: carrie.wardhaugh@ed.ac.uk
-
Glasgow, Vereinigtes Königreich, G51 4TF
- Noch keine Rekrutierung
- Queen Elizabeth University Hospital
-
Hauptermittler:
- Maytal Wolfe
-
Kontakt:
- Rebecca Baird
- E-Mail: ggc.mentalhealthresearch@nhs.scot
-
Liverpool, Vereinigtes Königreich, L7 8XP
- Noch keine Rekrutierung
- Royal Liverpool Hospital
-
Kontakt:
- Rachel Crick
- Telefonnummer: +44730 861 3597
- E-Mail: Rachel.Crick@merseycare.nhs.uk
-
Hauptermittler:
- Fabian Devlin
-
London, Vereinigtes Königreich, EC2Y 8EA
- Rekrutierung
- St Pancras Clinical Research
-
Hauptermittler:
- Martin Johnson
-
Kontakt:
- Participant Engagement Team
- Telefonnummer: +44 20 38651142
- E-Mail: studyinformation@stpancrasclinical.com
-
London, Vereinigtes Königreich, W1U 6RP
- Rekrutierung
- Clerkenwell Health - Baker Street
-
Hauptermittler:
- Alishah Suleman
-
Kontakt:
- Takunda Gwenhure
- Telefonnummer: +44 2038974867
- E-Mail: tgwenhure@clerkenwellhealth.com
-
Kontakt:
- Victor Jardim
- Telefonnummer: +44 2038974867
- E-Mail: vjardim@clerkenwellhealth.com
-
London, Vereinigtes Königreich, W1G9 RU
- Rekrutierung
- Re:Cognition Health
-
Hauptermittler:
- Dimitrios Paschos
-
Kontakt:
- Telefonnummer: +44-0800-802-1030
-
London, Vereinigtes Königreich, SE5 9RS
- Rekrutierung
- King's College London
-
Kontakt:
- Catheine Bird
- E-Mail: catherine.bird@kcl.ac.uk
-
Kontakt:
- Paige Seath
- E-Mail: paige.seath@kcl.ac.uk
-
Hauptermittler:
- James Rucker
-
London, Vereinigtes Königreich, W1G 8DR
- Zurückgezogen
- Clerkenwell Health - Welbeck Street
-
Newcastle upon Tyne, Vereinigtes Königreich, NE4 5PL
- Rekrutierung
- Edwardson Building - Campus for Ageing and Vitality
-
Kontakt:
- Victoria Wilson
- Telefonnummer: +44 191 246 8647
- E-Mail: victoria.wilson3@cntw.nhs.uk
-
Kontakt:
- Rebecca Woodhouse
- E-Mail: Rebecca.Woodhouse@cntw.nhs.uk
-
Hauptermittler:
- Mourad Wahba
-
Reading, Vereinigtes Königreich, RG7 8PA
- Rekrutierung
- Ascend Clinical Research
-
Hauptermittler:
- Pamela Walters
-
Kontakt:
- Alexandra Diaz
- Telefonnummer: +44 118 3045905
- E-Mail: adiaz@ascendclinical-research.com
-
Sheffield, Vereinigtes Königreich, S4 7QQ
- Rekrutierung
- Sheffield Health and Social Care NHS Foundation Trust
-
Hauptermittler:
- William Gann
-
Kontakt:
- Mishell Cunningham
- Telefonnummer: +44 114 271 6731
- E-Mail: mishell.cunningham@sheffieldpartnership.nhs.uk
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
Participants must meet all the following criteria to be included in the trial:
- Age18 to 85 years.
- Participant has a diagnosis of MDD (single or recurrent episode as defined by DSM-5 TR [if single episode, duration of ≥4 weeks and ≤24 months] and established as per evaluation by the Investigator. The first MDD episode must have occurred prior to age 60.
- Moderate to severe depression at Screening and Baseline, independently confirmed.
- Participants have been on a stable dose of antidepressant medication (label specified) at an adequate dose in the last 4 weeks prior to Screening and has had an inadequate response (less than 50% improvement), as judged by the Investigator.
- Participant has a body mass index (BMI) of 40 kg/m2 or less (BMI ≤40 kg/m2), inclusive, at Screening.
- Participant is able to refrain from nicotine use during the dosing session (up to 8 hours).
- Participants capable of producing sperm must use a condom plus spermicide during the trial and for 12 weeks after their final dose of trial medication, if their partner is a person of childbearing potential.
- Participants of childbearing potential who have a partner capable of producing sperm must agree to use a highly effective method of contraception in combination with the use of a condom plus spermicide during the trial and for 12 weeks after their final dose of trial medication. Such participants must have a negative pregnancy test at Screening and Day 1 prior to dosing.
- Participants of non-childbearing potential who are or were capable of producing eggs (ova) must have been postmenopausal or permanently sterile following hysterectomy, bilateral salpingectomy, or bilateral oophorectomy.
- Participants have provided written informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form.
Exclusion Criteria
Participants with any of the following characteristics/conditions will be excluded from trial participation:
- Current or previously diagnosed schizophrenia spectrum or other psychotic disorders, including schizophrenia, schizoaffective disorder, schizotypal disorder, schizophreniform disorder, brief psychotic disorder, current or previous history of bipolar disorder, or current borderline personality disorder.
- Participants with a medical diagnosis of attention deficit hyperactivity disorder (ADHD) will be excluded if currently taking medication for ADHD.
- Family history of schizophrenia, schizoaffective disorder, or bipolar disorder type 1 (first-degree relatives).
- Significant suicide risk within the past 6 months, during the Screening Period, or at Baseline; or (b) suicidal behaviors within 12 months of Screening; or (c) clinical assessment of significant suicidal risk during clinical interview; or (d) non-suicidal self-injury within 12 months of Screening.
- Current or previous diagnosis of treatment-resistant MDD, defined as failure to respond to 2 or more antidepressant treatments of 2 different classes given at an adequate dose (label specified) for an adequate duration as judged by the Investigator and clinical interview.
- Has had electroconvulsive treatment, transcranial magnetic stimulation, deep brain stimulation, or vagal nerve stimulation for any episode of MDD in the last 6 months.
- Currently receiving a monoamine oxidase inhibitor, tricyclic antidepressants, mirtazapine, trazodone, moclobemide, buspirone, or an antipsychotic or mood stabilizer. Note: if receiving these medications are for another indication, they must be discontinued ≥ 14 days or 5 half-lives, whichever is longer, prior to Day 1.
- Participant report of (or if available in medical record) exposure to psilocin, or 5-HT2a receptor agonists, or any other psychedelics, such as ayahuasca, mescaline, lysergic acid diethylamide, peyote, or 3,4-methylenedioxymethamphetamine, more than 10 times over the participant's lifetime or any psychedelic use within 12 months prior to Screening.
- Participant report of (or if available in medical record) treatment with ketamine or S-ketamine use within 6 months prior to Screening.
- Clinically relevant history of abnormal physical health interfering with the trial (including but not limited to, neurological, cardiovascular, respiratory, gastrointestinal [including dyspepsia or gastroesophageal reflux disease], hepatic, or renal disorder).
- Has hypothyroidism or hyperthyroidism, unless controlled on appropriate medication.
- Current diagnosis of uncontrolled hypertension or an arrhythmia, or clinically relevant abnormal results for heart rate.
- Participants have a presence or relevant history of organic brain disorders.
- Participant is taking or has taken OTC doses of 5-HTP or St John's Wort within prior to trial medication administration.
- Donation of blood or plasma within 4 weeks prior to first dosing and until 4 weeks after final dosing.
- Participants capable of producing sperm who will not abstain from sperm donation between first dosing and 12 weeks after final dosing.
- Participants of childbearing potential who are pregnant, breastfeeding, planning to conceive or unwilling to abstain from egg (ova) donation between first dosing and 12 weeks after final dosing.
- History of serotonin syndrome.
- Unwilling to consent to audio and video recording of psychological support and dosing sessions.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Vervierfachen
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Experimental Arm A CYB003 in 2 of 2 Dosing Sessions
Arm A participants will receive 8 mg of CYB003 in 2 of 2 medicine sessions, approximately three weeks apart. All Arm A participants will continue on their current antidepressants and receive psychological support throughout the study. |
CYB003 is a deuterated psilocin analog. Manualized psychological support performed by facilitator. |
|
Experimental: Experimental Arm B CYB003 in 2 of 2 Dosing Sessions
Experimental Arm B participants will receive 16 mg of CYB003 in 2 of 2 medicine sessions, approximately three weeks apart. All Arm B participants will continue on their current antidepressants and receive psychological support throughout the study. |
CYB003 is a deuterated psilocin analog. Manualized psychological support performed by facilitator. |
|
Placebo-Komparator: Placebo Comparator: Arm C Placebo in 2 of 2 Dosing Session
Participants will receive placebo in 2 of 2 medicine sessions, approximately three weeks apart. All Arm C participants will continue on their current antidepressants and receive psychological support throughout the study. Non-responders will be eligible to receive CYB003 in a subsequent extension trial. |
Manualized psychological support performed by facilitator. |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Montgomery-Asberg Depression Scale (MADRS)
Zeitfenster: Screening Day-45, Baseline, Day -1, Day 21, Day 42, Day 63 and Day 84/End of Trial.
|
The MADRS is a 10-item scale with ratings based on a clinical interview which moves from broadly phased questions about symptoms to more detailed ones allowing a precise rating of severity. The total score ranges 0-60, higher scores denote greater severity. |
Screening Day-45, Baseline, Day -1, Day 21, Day 42, Day 63 and Day 84/End of Trial.
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
The Beck Depression Inventory - Second Edition (BDI-II)
Zeitfenster: Day -1, Day 21, Day 42 and Day 84/End of Trial.
|
The Beck Depression Inventory-Second Edition (BDI-II) is a 21-question multiple-choice self-report inventory, assessing depressive symptoms and severity. Each question is scored on a scale value of 0 to 3, with higher total scores indicating more severe depressive symptoms. Each of the 21 items corresponding to a symptom of depression is summed to give a single score for the BDI-II, so the total score possible is 63 and minimum if everything is zero would be 0. |
Day -1, Day 21, Day 42 and Day 84/End of Trial.
|
|
The Clinical Global Impression Scale (CGI-S)
Zeitfenster: Screening Day-45, Baseline Day -1, Day 42, Day 84/End of Trial.
|
The Clinical Global Impression Scale is a clinician-rated instrument comprised of 3 global measures: severity of illness, global improvement and efficacy index. Only the severity of illness ang global improvement measures will be utilized for this trial. Higher score means more severe symptomology, worse outcome. CGI-S scoring is as follows:
|
Screening Day-45, Baseline Day -1, Day 42, Day 84/End of Trial.
|
|
The Generalized Anxiety Disorder 7-Item Scale (GAD-7)
Zeitfenster: Baseline Day -1, Day 21, Day 42, Day 63 and Day 84/End of Trial.
|
The Generalized Anxiety Disorder 7-Item Scale (GAD-7) is a 7-item self reported assessment that measures the severity of generalized anxiety disorder symptoms. Participants respond to each item using a 4-point scale from 0 to 3. Participants choose one of 4 severity scores associated with problems related to the common anxiety disorders to indicate the degree to which these problems caused functional and/or social difficulties. A total score is obtained by the sum of all total column values, higher scores indicate more functional/social impairment/difficulties. Score range is as follows: Scores represent: 0 - 4 = Minimal anxiety 5 - 9 = Mild anxiety 10 - 14 = Moderately anxiety 15 - 21 = Severe anxiety |
Baseline Day -1, Day 21, Day 42, Day 63 and Day 84/End of Trial.
|
|
The Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF)
Zeitfenster: Day -1, Day 21, Day 42 and Day 84/End of Trial.
|
The original Quality of Life Enjoyment and Satisfaction Questionnaire is a 93 item, participant facing, self reported measure used to evaluate intervention-related changes in quality of life, divided int the following sections: physical health, feelings, work, household duties, school, leisure time activities, social relations and general activities. The Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) version will be used in this trial. Each item rated on a 5-point scale ranging from 1 (very poor) to 5 (very good), higher score indicates greater satisfaction. The scoring of the Q-LES-Q-SF involves summing only the first 14 items to yield a raw total score. The last two items are not included in the total score but are standalone items. The raw total score ranges from 14 to 70. So the minimum raw score on the Q-LES-Q-SF is 14, and the maximum score is 70 |
Day -1, Day 21, Day 42 and Day 84/End of Trial.
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Mitarbeiter
Mitarbeiter
Ermittler
Ermittler
- Studienleiter: Felix Mazer, Cybin IRL Limited
Publikationen und hilfreiche Links
Nützliche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- CYB003-003
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .